- Home
- NMT vs ALGS Comparison
NMT vs ALGS Comparison
Compare NMT & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- ALGS
- Stock Information
- Founded
- NMT 1993
- ALGS 2018
- Country
- NMT United States
- ALGS United States
- Employees
- NMT N/A
- ALGS N/A
- Industry
- NMT Finance/Investors Services
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- NMT Finance
- ALGS Health Care
- Exchange
- NMT Nasdaq
- ALGS Nasdaq
- Market Cap
- NMT 110.6M
- ALGS 118.8M
- IPO Year
- NMT N/A
- ALGS 2020
- Fundamental
- Price
- NMT $11.77
- ALGS $10.51
- Analyst Decision
- NMT
- ALGS Strong Buy
- Analyst Count
- NMT 0
- ALGS 1
- Target Price
- NMT N/A
- ALGS $70.00
- AVG Volume (30 Days)
- NMT 19.1K
- ALGS 241.1K
- Earning Date
- NMT 01-01-0001
- ALGS 03-10-2025
- Dividend Yield
- NMT 3.21%
- ALGS N/A
- EPS Growth
- NMT N/A
- ALGS N/A
- EPS
- NMT N/A
- ALGS N/A
- Revenue
- NMT N/A
- ALGS $3,945,000.00
- Revenue This Year
- NMT N/A
- ALGS N/A
- Revenue Next Year
- NMT N/A
- ALGS N/A
- P/E Ratio
- NMT N/A
- ALGS N/A
- Revenue Growth
- NMT N/A
- ALGS N/A
- 52 Week Low
- NMT $9.05
- ALGS $6.76
- 52 Week High
- NMT $10.93
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- NMT 46.08
- ALGS 22.23
- Support Level
- NMT $11.85
- ALGS $9.51
- Resistance Level
- NMT $11.89
- ALGS $18.75
- Average True Range (ATR)
- NMT 0.09
- ALGS 1.90
- MACD
- NMT -0.02
- ALGS -0.41
- Stochastic Oscillator
- NMT 12.96
- ALGS 7.76
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes by investing in a portfolio of municipal obligations issued by state and local government authorities within a single state or certain U.S. territories.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.